| [Maximal androgen blockade little influences bone mineral density in prostate cancer patients]. | |
| | |
MedLine Citation:
|
PMID: 23214245 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: To determine the influence of maximal androgen blockade (MAB) on bone mineral density (BMD) in men with prostate cancer. METHODS: We enrolled 40 men with prostate cancer treated by MAB for 7 to 12 months. We obtained the laboratory results of PSA, testosterone, serum calcium and phosphorus, 24-h urine calcium and phosphorus, alkaline phosphatase, and parathyroid hormone, measured the BMD of the lumbar spine and femoral neck by dual energy X-ray absorptiometry, recorded pain scores, and compared the results before and after the treatment. RESULTS: Before MAB treatment, 5 (12.5%) of the patients met the BMD criteria of lumbar spine (L2-4) osteopenia, 8 (20%) lumbar spine (L2-4) osteoporosis, 13 (32.5%) left femoral neck osteopenia, and 15 (37.5%) left femoral neck osteoporosis. The PSA and testosterone levels were decreased from (52.9 +/- 69.9) microg/L and (18.9 +/- 6.5) nmol/L before MAB to (1.5 +/- 1.6) microg/L and (1.9 +/- 1.3) nmol/L after it (P<0.05). There were no statistically significant differences before and after MAB in the levels of serum calcium and phosphorus, 24-h urine calcium and phosphorus, alkaline phosphatase, and parathyroid hormone (P>0.05), nor in the BMD levels of the lumbar spine ([1.1 +/- 0.1] vs [1.1 +/- 0.2] g/cm2) and femoral neck ([0.8 +/- 0.2] vs [0.8 +/- 0.1] g/cm2), nor in the pain score ([0.6 +/- 0.2] vs [0.7 +/- 0.1], P>0.05). CONCLUSION: MAB treatment (range from 7 to 12 months) has no significant influence on BMD in men with prostate cancer, but BMD should be measured before MAB. |
| | |
Authors:
|
Guo-Feng Sun; Bing Yang; He Zhu; Ning-Chen Li; Yan-Qun Na |
Publication Detail:
|
Type: English Abstract; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Zhonghua nan ke xue = National journal of andrology Volume: 18 ISSN: 1009-3591 ISO Abbreviation: Zhonghua Nan Ke Xue Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-12-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101093592 Medline TA: Zhonghua Nan Ke Xue Country: China |
Other Details:
|
Languages: chi Pagination: 978-81 Citation Subset: IM |
Affiliation:
|
Wu Jieping Urology Medical Center, Shougang Hospital of Peking University, Beijing 100041, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: [Screening of Y chromosome microdeletions in infertile males with varicocele].
Next Document: [Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis].